Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506.
The immunosuppressive agent cyclosporin A (CsA) is reportedly associated with clinically adverse effects on circulating lipid and apolipoprotein concentrations. To date few data have been reported concerning the effects on lipid metabolism of the new macrolide immunosuppressive agent FK 506, and no comparative studies of the effects of these drugs have been performed. In consideration of the pivotal role of the liver in lipid metabolism, we measured fasting serum lipids and apolipoproteins a median of 8 (range 5 to 9) months after the operation in 20 clinically stable liver transplant recipients randomly allocated to maintenance immunosuppression with CsA +/- azathioprine (n = 10) or FK 506 (n = 10). To avoid the confounding effects of corticosteroids on lipid metabolism, prednisolone was withdrawn at least 6 weeks beforehand in each case. Ten healthy volunteers matched for age and body mass index served as control subjects. Serum total cholesterol concentration was significantly lower in both the CsA (p < 0.001) and FK 506 (p < 0.05) treatment groups when compared with the healthy control subjects. Serum high-density lipoprotein (HDL) cholesterol concentration was also significantly lower in both the CsA (p < 0.005) and FK 506 (p < 0.01) treatment groups. Neither the ratio of serum total cholesterol to HDL cholesterol nor the fasting triglyceride concentrations were significantly different (p > 0.1) from those of the healthy control subjects for either transplant group. Serum apolipoprotein B level was lower than that of the control group in both the CsA (p < 0.005) and FK 506 groups (p = 0.06).(ABSTRACT TRUNCATED AT 250 WORDS)
Krentz
A J
AJ
General Hospital, Birmingham, England.
Cramb
R
R
Dousset
B
B
Mayer
D
D
McMaster
P
P
Buckels
J
J
Smith
J M
JM
Nattrass
M
M
D001053:Apolipoproteins / Q000032:analysis* / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000494:pharmacology*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000378:metabolism; D016031:Liver Transplantation; D016559:Tacrolimus / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008055:Lipids; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; D016559:Tacrolimus